Mr. Justin S. Lee
President
Clinical Resolution Laboratory Inc.
1400 W. Lambert Rd., Ste. C
Brea , CA 92821-2874
United States
justin@clinicalresolution.comFEI 3005727243Issued Mar 1, 2022Division of Pharmaceutical Quality Operations IV
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3005727243.
Violations9
Issue DateMar 1, 2022
Product TypeDrugs
StatusOpen
Letter Details
Firm
Clinical Resolution Laboratory Inc.
Location
Mr. Justin S. Lee
President
Clinical Resolution Laboratory Inc.
1400 W. Lambert Rd., Ste. C
Brea , CA 92821-2874
United States
justin@clinicalresolution.com
FEI Number
3005727243
Country
United States
Issue Date
March 01, 2022
Issuing Office
Division of Pharmaceutical Quality Operations IV
Product Type
Drugs
Status
Open
Summary
Clinical Resolution Laboratory Inc., a drug manufacturer in Brea, California, was cited for significant Current Good Manufacturing Practice (CGMP) violations that rendered their finished pharmaceutical products adulterated. During an April 2021 inspection, the FDA found that the company failed to establish adequate written procedures for production and process control and could not provide data demonstrating that their over-the-counter drug manufacturing processes had been validated. Additionally, certain products were identified as unapproved new drugs and misbranded. The company's May 2021 response to the inspection findings was determined inadequate due to insufficient detail and evidence of corrective actions necessary to achieve compliance.
Clinical Resolution Laboratory Inc. FDA Warning Letter, March 1, 2022